Regencell Bioscience Holdings Limited Ordinary Shares (RGC)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with what is known. Regencell is a Hong Kong TCM researcher with 10 employees, focused on neurocognitive disorders such as ADHD and autism. There is no filed revenue-growth or profit-growth record, and the computed Lynch category is none because there are only zero years of filed results. That is a huge red flag: I cannot judge earning power or consistency. Financial health is poor on returns: FairStock calculations show ROE of -177.66%, ROCE of -84.97%, and a Piotroski F-Score of 1/9. The balance sheet has D/E of 0.32, which is a modest positive, and the Altman Z-Score is 4655.46, but the latter is so extreme it may reflect a data quirk rather than a durable competitive advantage. At the 2026-10-13 close of $8.19, FairStock calculated a P/E of -819 and a P/B of 2,895; that is not a value investor's margin of safety. The market cap is $13.9B against negative earnings, so the price is priced for a future that has not yet appeared in filings. The FairStock Score is 23/100. The 52-week range of $4.51 to $69.00 and beta of 1.43 suggest speculation and volatility, not a stable franchise. The only potential moat would be proprietary TCM treatments and approvals, but I have no filed commercial proof. Without multi-year revenue, profits, and cash flow, this looks more like a lottery ticket than a business I can evaluate. I would need many more years of filed results before considering it a Graham-style investment.

In plain English: Regencell Bioscience is a Hong Kong company with 10 employees trying to develop and sell traditional Chinese medicine for brain-related conditions like ADHD and autism. The business looks very weak today: it has no filed growth history, loses money, and shows negative returns. At $8.19 on 2026-10-13, the price looks very expensive compared with the small or negative profits and the company's accounting value, so it depends on future promises rather than current results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer